• Explore /
  • Poster
  • / Exon-16-skipping <em>ERBB2</em> (<em>ERBB2</em>ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).

Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Xin Zhao

Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Xin Zhao , Linling Jin , Man Yu , Qiuxiang Ou , Hua Bao , Xue Wu , Yang Shao , Min Fan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9528)

DOI

10.1200/JCO.2020.38.15_suppl.9528

Abstract #

9528

Poster Bd #

294

Abstract Disclosures

Similar Posters

First Author: Akito Hata

First Author: Jingran Ji

First Author: Qiuxiang Ou

Poster

2016 ASCO Annual Meeting

Role of <i>TP53</i> mutations in predicting response to TKI treatment in <i>EGFR</i>-mutated NSCLC patients.

Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.

First Author: Paola Ulivi